New PNH drug VSA012 enters early human testing
NCT ID NCT06848296
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new drug called VSA012 in about 50 adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder that destroys red blood cells. The study includes people who have not used complement inhibitors before or who still have low hemoglobin despite prior treatment. The main goals are to check safety and see if VSA012 can reduce markers of red blood cell breakdown and improve anemia.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- VSA012 injection
- What this could lead to
- If successful, this could point toward a new treatment option for PNH that controls red blood cell destruction and improves anemia.
- What could go wrong
- This is a very early Phase 1 trial with only 50 participants, so safety and effectiveness are not yet proven. The drug may cause side effects or fail to show benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, PNH are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
-
The First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new pill tame a rare blood disease? early safety trial begins
- New drug pegcetacoplan tested in teens with rare blood disorder
- New pill CMS-D017 enters first human safety trials
- Thousands with blood diseases to be tracked in massive chinese registry
- New drug SLN12140 aims to control PNH in early trial
- New siRNA drug ADX-038 enters human trials for PNH anemia